Dejima Hitoshi, Iinuma Hisae, Kanaoka Rie, Matsutani Noriyuki, Kawamura Masafumi
Department of Surgery, Teikyo University School of Medicine, Tokyo 173-0003, Japan.
Oncol Lett. 2017 Mar;13(3):1256-1263. doi: 10.3892/ol.2017.5569. Epub 2017 Jan 4.
Predictive biomarkers for the recurrence of non-small cell lung cancer (NSCLC) in patients who have received curative resection are important for cancer treatment. The functional microRNAs (miRNAs/miRs) in the exosomes of plasma and serum samples are of interest as stable and non-invasive biomarkers for recurrence in cancer patients. The aim of the present study was to clarify the usefulness of plasma exosomal miRNAs as biomarkers for the prediction of recurrence in NSCLC following curative resection. First, microarray-based expression profiling of miRNAs derived from exosomes in the plasma of 6 patients was employed to identify a biomarker that distinguishes between patients with and without NSCLC recurrence. In the miRNA microarray analyses, the exosomal miR-21 and miR-4257 levels of the NSCLC patients showed marked upregulation in those individuals with recurrence compared with those without recurrence and healthy individuals. These two miRNAs were thus selected as recurrence-specific biomarkers and their potential was evaluated in a separate cohort of 195 NSCLC patients. In comparison to the levels in 30 healthy individuals, exosomal miR-21 and miR-4257 levels showed a significant increase in the NSCLC patients (P<0.01). When evaluating the clinicopathological significance of these miRNAs, exosomal miR-21 showed a significant association with tumor size and tumor-node-metastasis (TNM) stage (P<0.05). Exosomal miR-4257 showed a significant association with histological type, lymphatic invasion and TNM stage (P<0.05). The disease-free survival (DFS) rates of high exosomal miR-21 patients were significantly worse than those of low exosomal miR-21 patients (P<0.05), and the DFS rates of patients with high exosomal miR-4257 levels were significantly worse than those with low exosomal miR-4257 levels (P<0.01). In the Cox multivariate analysis, plasma exosomal miR-21 and miR-4257 expression showed a significance association with DFS (P<0.05). These results suggest that plasma exosomal miR-21 and mir-4257 expression has potential as a predictive biomarker for recurrence in NSCLC patients who have received curative resection.
对于接受根治性切除的非小细胞肺癌(NSCLC)患者,预测其复发的生物标志物对癌症治疗具有重要意义。血浆和血清样本外泌体中的功能性微小RNA(miRNA/miR)作为癌症患者复发的稳定且非侵入性生物标志物备受关注。本研究的目的是阐明血浆外泌体miRNA作为预测NSCLC根治性切除术后复发的生物标志物的实用性。首先,对6例患者血浆中外泌体来源的miRNA进行基于微阵列的表达谱分析,以鉴定区分有或无NSCLC复发患者的生物标志物。在miRNA微阵列分析中,NSCLC患者的外泌体miR-21和miR-4257水平在复发患者中较未复发患者和健康个体显著上调。因此,这两种miRNA被选为复发特异性生物标志物,并在另一组195例NSCLC患者中评估其潜力。与30例健康个体的水平相比,NSCLC患者的外泌体miR-21和miR-4257水平显著升高(P<0.01)。在评估这些miRNA的临床病理意义时,外泌体miR-21与肿瘤大小和肿瘤-淋巴结-转移(TNM)分期显著相关(P<0.05)。外泌体miR-4257与组织学类型、淋巴浸润和TNM分期显著相关(P<0.05)。外泌体miR-21水平高的患者无病生存期(DFS)率显著低于外泌体miR-21水平低的患者(P<0.05),外泌体miR-4257水平高的患者DFS率显著低于外泌体miR-4257水平低的患者(P<0.01)。在Cox多变量分析中,血浆外泌体miR-21和miR-4257表达与DFS显著相关(P<0.05)。这些结果表明,血浆外泌体miR-21和miR-4257表达有潜力作为接受根治性切除的NSCLC患者复发的预测生物标志物。